Floatz logo

Quizartinib

Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication

M.D. Anderson Cancer CenterSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication cohort.

Asset / SponsorPhaseRating
Gilteritinib
The First Affiliated Hospital of Soochow University
Phase 3BB
Azacitidine
French Innovative Leukemia Organisation
Phase 2BB
Cytarabine
First Affiliated Hospital of Zhejiang University
Phase 3BB
Sorafenib
The First Affiliated Hospital of Soochow University
Phase 3BB
Daunomycin
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB

View all 21 →

Same molecule, other indications

Quizartinib is also rated in:

myelodysplastic syndromeActive
BB
Indicative · Phase 2/3
67 / 100
View asset →
acute myeloid leukemiaActive
B
Indicative · Phase 3
63 / 100
View asset →
childhood acute myeloid leukemiaActive
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →